HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Lowers Price Target to $2

Benzinga ·  10/21/2023 01:54

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (OTC:ARDS) with a Buy and lowers the price target from $10 to $2.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment